Abstract
A gadolinium-based contrast is the preferred agent when differentiating acute neu-rological diseases. Since the renal route is the main pathway for excretion of gadolini-um chelates, prolonged extracellular distribution of gadolinium has previously been reported in dialysis-dependent patients. Hence, gadolinium-based contrast agents are used cautiously in patients with known renal disease. Retention of gadolinium manifests as increased fluid-attenuated inversion recovery (FLAIR) signal intensity in the subarachnoid space, leading to diagnostic errors. Here, we describe a patient who presented to our emergency room with an acute cerebral infarction. Enhanced brain magnetic resonance imaging performed 2 days later revealed high signal inten-sity in the cerebrospinal fluid spaces on follow-up FLAIR images.
REFERENCES
1.Ong EM., Yeh IB. High signal in the cerebrospinal fluid following prior gadolinium administration in a patient with renal impairment. Singapore Med J. 2007. 48:e296–e298.
2.Rai AT., Hogg JP. Persistence of gadolinium in CSF: a diagnos-tic pitfall in patients with end-stage renal disease. AJNR Am J Neuroradiol. 2001. 22:1357–1361.
3.Lev MH., Schaefer PW. Subarachnoid gadolinium enhance-ment mimicking subarachnoid hemorrhage on FLAIR MR im-ages. Fluid-attenuated inversion recovery. AJR Am J Roent-genol. 1999. 173:1414–1415.
4.Tombach B., Bremer C., Reimer P., Schaefer RM., Ebert W., Geens V, et al. Pharmacokinetics of 1M gadobutrol in patients with chronic renal failure. Invest Radiol. 2000. 35:35–40.